Viewing Study NCT06118619



Ignite Creation Date: 2024-05-06 @ 7:43 PM
Last Modification Date: 2024-10-26 @ 3:13 PM
Study NCT ID: NCT06118619
Status: RECRUITING
Last Update Posted: 2023-11-09
First Post: 2023-11-01

Brief Title: A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis
Sponsor: SPP Pharmaclon Ltd
Organization: SPP Pharmaclon Ltd

Study Overview

Official Title: A Multicenter Clinical Trial of Recombinant Human Interferon Gamma Ingaron in Pulmonary Tuberculosis
Status: RECRUITING
Status Verified Date: 2023-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main purpose of testing To confirm the effectiveness and safety of the drug Ingaron when used in patients hospitalized at the research center for various reasons
Detailed Description: Monitoring of a patient in a hospital is carried out daily by the attending physician during the entire period of the patients stay at the research center When prescribing the drug Ingaron the researcher must follow the instructions for use of the drug As part of 4 control observations to assess effectiveness and safety

1st on the 1st day of using the drug Ingaron and starting anti-tuberculosis therapy
2nd on the 30th - 31st day of therapy
3rd after 2 months of therapy
4th final after 3 months of follow-up After each of the 3 visits the research doctor saves the data necessary for further evaluation

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None